Join us June 10-13, 2017 in Washington, DC for the annual NF Conference, a global event attracting more than 300 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis.
The Children's Tumor Foundation (CTF) is hosting the 2016 NF Conference/Forum, the largest worldwide meeting dedicated entirely to neurofibromatosis (NF), a genetic disorder that affects 1 in 3,000 people and causes tumors to grow throughout the body.
Over half of patients treated with selumetinib in phase I trial see reduction in plexiform neurofibromas
New York, June 8, 2015 – As hundreds of the world’s leading NF experts convene in Monterey, California for the NF Conference, the largest gathering dedicated to neurofibromatosis (NF), it was announced today that for the first time in the history of the treatment of plexiform neurofibromas (PNs), over 50% of patients saw decreased volume in these inoperable tumors. In a presentation titled “The Promise of MEK: Therapeutics for NF1”, Brigitte C. Widemann, MD, of the National Cancer Institute (NCI), reported that response data in a phase I trial for children and young adults is showing decreases in tumor volume. Anecdotal improvement in function, and reduction in PN related pain and disfigurement has also been observed.
Poster sessions are an opportunity for researchers to showcase their work in Basic and Clinical Sciences to an audience of NF researchers. A panel of judges select the top posters, and these investigators are invited to present their work in front of the full conference.
Below are the top posters at the 2015 NF Conference in Clinical and Basic Sciences.